Identification of active components in Longxue Tongluo Capsules against ischemic brain injury based on component-activity relationship.
10.19540/j.cnki.cjcmm.20181108.004
- Author:
Jing SUN
1
;
Xiao-Nan CHEN
2
;
Jia-Ni LIU
3
;
Peng-Wei GUAN
2
;
Chao-Chao WANG
2
;
Bo PAN
2
;
Dao-Ran PANG
2
;
Shan-Shan LI
2
;
Jiao ZHENG
2
;
Wen-Zhe HUANG
4
;
Peng-Fei TU
5
;
Jun LI
2
Author Information
1. Modern Research Center for Traditional Chinese Medicine,School of Chinese Materia Medica,Beijing University of Chinese Medicine Beijing 100029,China Institute of Food Science and Technology,Chinese Academy of Agricultural Sciences Beijing 100193,China.
2. Modern Research Center for Traditional Chinese Medicine,School of Chinese Materia Medica,Beijing University of Chinese Medicine Beijing 100029,China.
3. Institute of Food Science and Technology,Chinese Academy of Agricultural Sciences Beijing 100193,China.
4. Jiangsu Kanion Pharmaceutical Co.,Ltd. Lianyungang 222001,China.
5. Modern Research Center for Traditional Chinese Medicine,School of Chinese Materia Medica,Beijing University of Chinese Medicine Beijing 100029,China Jiangsu Kanion Pharmaceutical Co.,Ltd. Lianyungang 222001,China.
- Publication Type:Journal Article
- Keywords:
Longxue Tongluo Capsules;
component-activity relationship;
grey relation analysis;
ischemic brain injury;
partial least square;
resina draconis
- MeSH:
Brain Ischemia;
drug therapy;
Capsules;
Cell Line;
Drugs, Chinese Herbal;
pharmacology;
Glucose;
Human Umbilical Vein Endothelial Cells;
drug effects;
Humans;
Microglia;
drug effects;
Oxygen
- From:
China Journal of Chinese Materia Medica
2019;44(1):150-157
- CountryChina
- Language:Chinese
-
Abstract:
Ten fractions(A-J) were prepared by separation of Longxue Tongluo Capsules(LTC) by using silica gel column chromatography and orthogonal experimental design,showing similar chemical profiles with different abundances of peaks.These ten samples were assessed with UHPLC-QE OrbitrapHRMS for 97 common peaks.For the pharmacological activity experiment,three kinds of in vitro cell models including lipopolysaccharide(LPS)-induced BV-2 microglial cells NO release model,oxygen-glucose deprivation/reoxygenation(OGD/R)-treated HUVEC vascular endothelial cells injury model,and OGD/R-treated PC-12 nerve cells injury model were employed to evaluated the bioactivity of each fraction.Based on the contribution of each identified component,grey relation analysis and partial least squares(PLS) analysis were performed to establish component-activity relationship of LTC,identify the potential active components.After that,validation of the potential active components in LTC was carried out by using the same models.The results indicated that 4 phenolic compounds including 7,4'-dihydroxyhomoisoflavanone,loureirin C,4,4'-dihydroxy-2,6-dimethoxydihydrochalcone,and homoisosocotrin-4'-ol,might be the active components for anti-neuroinflammation effect;five phenolic compounds such as 3,5,7,4'-tetrahydroxyhomoisoflavanone,loureirin D,7,4'-dihydroxyhomoisoflavane,and 5,7-dihydroxy-4'-methoxy-8-methyflavane,might have positive effects on the vascular endothelial injury;three phenolic compounds including 5,7,4'-trihydroxyflavanone,7,4'-dihydroxy-5-methoxyhomoisoflavane,and loureirin D,might be the active components in LTC against neuronal injury.
